First-in-class investigational therapeutic shows early promise for lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail